Get the Stockscreener App
0.9615
1.82%
-0.0178
After Hours:
1.00
0.0385
+4.00%
Immunic Inc stock is traded at $0.9615, with a volume of 644.38K.
It is down -1.82% in the last 24 hours and up +37.85% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$0.9793
Open:
$0.9981
24h Volume:
644.38K
Relative Volume:
0.37
Market Cap:
$92.13M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.4557
EPS:
-2.11
Net Cash Flow:
$-71.16M
1W Performance:
-3.56%
1M Performance:
+37.85%
6M Performance:
-5.74%
1Y Performance:
-31.32%
1-Day Range:
$0.95
$1.00
1-Week Range:
$0.9426
$1.18
52-Week Range:
$0.561
$2.11
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.9615 | 103.48M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
How Immunic Inc. stock performs during market volatilityShort Term Trading Opportunity Watch Sees Shift - beatles.ru
What is the dividend policy of Immunic Inc. stockBuild wealth with long-term growth strategies - jammulinksnews.com
What are analysts’ price targets for Immunic Inc. in the next 12 monthsCapitalize on emerging market trends - jammulinksnews.com
Should I hold or sell Immunic Inc. stock in 2025Triple-digit profit margins - jammulinksnews.com
Is it the right time to buy Immunic Inc. stockFree Predictions - jammulinksnews.com
What is Immunic Inc. company’s growth strategyBreakthrough profit margins - jammulinksnews.com
When is Immunic Inc. stock expected to show significant growthIdentify safe investments with exceptional yields - jammulinksnews.com
What is the risk reward ratio of investing in Immunic Inc. stockGame-changing returns - jammulinksnews.com
Is Immunic Inc. a growth stock or a value stockAchieve rapid portfolio growth with smart picks - jammulinksnews.com
What are the technical indicators suggesting about Immunic Inc.Free Consultation - jammulinksnews.com
Immunic, Inc.'s (NASDAQ:IMUX) market cap touched US$103m last week, benefiting both individual investors who own 55% as well as institutions - simplywall.st
Immunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS Trial - Insider Monkey
What drives Immunic Inc. stock priceRapid return acceleration - Autocar Professional
What analysts say about Immunic Inc. stockRecord-breaking gains - PrintWeekIndia
How Immunic Inc. stock reacts to Fed policy changesPowerful profit generation - jammulinksnews.com
Immunic Inc. Stock Analysis and ForecastRapid growth opportunities - Autocar Professional
How high can Immunic Inc. stock price go in 2025Accelerated earnings growth - jammulinksnews.com
Is Immunic Inc. a good long term investmentBreakthrough profits - PrintWeekIndia
Immunic, Inc. shares fall 2.01% premarket after AstraZeneca's immune disorder drug succeeds in late-stage trial. - AInvest
12 Best Penny Stocks Under $1 to Buy Now - Insider Monkey
World Brain Day: Immunic targets MS with new therapy - Proactive financial news
IMUX’s Stock Market Puzzle: Piecing Together 2025’s Performance - investchronicle.com
What makes Immunic Inc. stock price move sharplyValue Pick Scanner - Newser
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunic Inc Stock (IMUX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tardio Jason | President and COO |
Jun 05 '25 |
Buy |
0.79 |
12,512 |
9,884 |
12,512 |
| Vitt Daniel | CEO and Director |
Jun 04 '25 |
Buy |
0.77 |
15,000 |
11,550 |
29,000 |
| Neermann Joerg | Director |
Jun 04 '25 |
Buy |
0.77 |
70,000 |
53,900 |
170,000 |
| Neermann Joerg | Director |
Jun 05 '25 |
Buy |
0.76 |
30,000 |
22,800 |
200,000 |
| Whaley Glenn | Chief Financial Officer |
Jun 03 '25 |
Buy |
0.71 |
45,000 |
32,076 |
95,510 |
| Rudick Richard Alan | Director |
Jun 03 '25 |
Buy |
0.70 |
143,075 |
100,024 |
230,375 |
| Rudick Richard Alan | Director |
Nov 12 '24 |
Buy |
1.15 |
87,300 |
100,369 |
87,300 |
0.23%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):